Michael Goggins

Johns Hopkins University

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index134

i10-index349

Publications1,049

Citations68,917

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 52

Data from Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study
2026-06-15
Supplementary Data from Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study
2026-06-15
Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging
Clinical Cancer Research · 2026-04-27
Supplementary Figures S1-S14 from Detecting Liver Cancer Using Cell-Free DNA Fragmentomes
2025-12-11
Supplementary Tables from Detecting Liver Cancer Using Cell-Free DNA Fragmentomes
2025-12-11
Supplementary Table S3 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S3 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S2 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S6 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S5 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S1 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S4 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S1 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Data from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S4 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Data Tables S1-S5 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25
Supplementary Data 2 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25
Supplementary Data 1 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25
Pancreas Part Segmentation Under Federated Learning Paradigm
Lecture notes in computer science · 2025-11-13
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
JNCI Journal of the National Cancer Institute · 2025-11-08 · 1 citations

Open author page on OpenAlex →